Grifols (GRFS) Long-Term Deferred Tax (2009 - 2025)
Grifols (GRFS) posted Long-Term Deferred Tax of $484.2 million for Q4 2025, up 32.5% quarter-over-quarter from $365.5 million in Q4 2024, and up 32.5% year-on-year from $365.5 million in Q4 2024.
Grifols (GRFS) Long-Term Deferred Tax (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Long-Term Deferred Tax for 16 consecutive years, with $484.2 million the latest figure, recorded in Q4 2025.
- Long-Term Deferred Tax for Q4 2025 came in at $484.2 million, up 32.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $484.2 million (up 32.5% YoY), and the FY2025 annual result was $484.2 million, up 32.5% from the prior year.
- Long-Term Deferred Tax was $484.2 million for Q4 2025 at Grifols, up from $365.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $484.2 million in Q4 2025 and troughed at $174.5 million in Q4 2021.
- Average Long-Term Deferred Tax over 5 years is $305.2 million, with a median of $323.1 million recorded in 2023.
- Year-over-year, Long-Term Deferred Tax fell 2.4% in 2021 and jumped 81.06% in 2023.
- Over 5 years, Long-Term Deferred Tax stood at $174.5 million in 2021, then increased by 2.29% to $178.5 million in 2022, then jumped by 81.06% to $323.1 million in 2023, then rose by 13.1% to $365.5 million in 2024, then jumped by 32.5% to $484.2 million in 2025.
- Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $484.2 million in Q4 2025, $365.5 million in Q4 2024, and $323.1 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 484.24 Mn |
| Dec 31, 2024 | 365.46 Mn |
| Dec 31, 2023 | 323.14 Mn |
| Dec 31, 2022 | 178.46 Mn |
| Dec 31, 2021 | 174.46 Mn |
| Dec 31, 2020 | 178.75 Mn |
| Dec 31, 2019 | 136.17 Mn |
| Dec 31, 2018 | 128.45 Mn |
| Jun 30, 2018 | 80.03 Mn |
| Dec 31, 2017 | 77.90 Mn |
| Jun 30, 2017 | 85.92 Mn |
| Dec 31, 2016 | 72.58 Mn |
| Sep 30, 2016 | 76.38 Mn |
| Jun 30, 2016 | 74.38 Mn |
| Dec 31, 2015 | 73.21 Mn |
| Sep 30, 2015 | 74.84 Mn |
| Jun 30, 2015 | 79,576.80 |
| Mar 31, 2015 | 92.69 Mn |
| Dec 31, 2014 | 103.04 Mn |
| Sep 30, 2014 | 149.28 Mn |